Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $4.65 in the prior trading day, Third Harmonic Bio Inc (NASDAQ: THRD) closed at $3.25, down -30.11%. In other words, the price has decreased by -$30.11 from its previous closing price. On the day, 14.19 million shares were traded. THRD stock price reached its highest trading level at $3.55 during the session, while it also had its lowest trading level at $3.18.
Ratios:
Our goal is to gain a better understanding of THRD by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 42.50 and its Current Ratio is at 42.50. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On August 09, 2024, Morgan Stanley Upgraded its rating to Overweight which previously was Equal-Weight and also upped its target price recommendation from $12 to $20.
On June 18, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $23.Stifel initiated its Buy rating on June 18, 2024, with a $23 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 08 ’24 when Conner Edward R. sold 2,117 shares for $15.00 per share. The transaction valued at 31,755 led to the insider holds 0 shares of the business.
BVF PARTNERS L P/IL sold 1,000,000 shares of THRD for $14,300,000 on Oct 29 ’24. The See Explanation of Responses now owns 176,692 shares after completing the transaction at $14.30 per share. On Oct 28 ’24, another insider, Conner Edward R., who serves as the Chief Medical Officer of the company, sold 2,673 shares for $15.00 each. As a result, the insider received 40,095 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, THRD now has a Market Capitalization of 146439808 and an Enterprise Value of -146250160.
Stock Price History:
The Beta on a monthly basis for THRD is 2.70, which has changed by -0.5094937 over the last 52 weeks, in comparison to a change of 0.21313763 over the same period for the S&P500. Over the past 52 weeks, THRD has reached a high of $16.94, while it has fallen to a 52-week low of $4.57. The 50-Day Moving Average of the stock is -62.72%, while the 200-Day Moving Average is calculated to be -72.32%.
Shares Statistics:
The stock has traded on average 245.40K shares per day over the past 3-months and 271920 shares per day over the last 10 days, according to various share statistics. A total of 44.73M shares are outstanding, with a floating share count of 16.76M. Insiders hold about 62.80% of the company’s shares, while institutions hold 40.12% stake in the company. Shares short for THRD as of 1738281600 were 3569036 with a Short Ratio of 14.35, compared to 1735603200 on 3590117. Therefore, it implies a Short% of Shares Outstanding of 3569036 and a Short% of Float of 15.83.
Earnings Estimates
Third Harmonic Bio Inc (THRD) is presently subject to a detailed evaluation by 3.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.34 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$0.96 and -$1.23 for the fiscal current year, implying an average EPS of -$1.1. EPS for the following year is -$1.39, with 3.0 analysts recommending between -$1.1 and -$1.62.
